Drug intelligence / Profile preview

CYCU-3

Development stage: Unknown
Modality: Inorganic Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

CYCU-3 is an aluminum-based metal-organic framework (Al-MOF) that functions as a coordination polymer matrix for drug encapsulation and controlled delivery. It is primarily investigated for its ability to form solid-state complexes with gemcitabine, a cytidine analog used in cancer treatment. By encapsulating the drug through non-covalent interactions at its O-H and COO- groups, CYCU-3 facilitates a delayed release profile, which aims to mitigate the 'burst effect' and systemic side effects associated with conventional gemcitabine administration. Research has demonstrated that CYCU-3-gemcitabine complexes exhibit time-dependent cytotoxicity against pancreatic cancer cells (PANC-1) in vitro.

Other names: Al-MOF CYCU-3Aluminum metal-organic framework CYCU-3

Beyond the preview

Go deeper on CYCU-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYCU-3.

Explore the full profile